| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
128,920,000 |
| Market
Cap: |
1.74(B) |
| Last
Volume: |
72,500 |
Avg
Vol: |
72,298 |
| 52
Week Range: |
$6.68 - $35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TG Therapeutics is a commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, Co. has received approval from the U.S. Food and Drug Administration for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
100,000 |
100,000 |
| Total Buy Value |
$0 |
$0 |
$1,013,000 |
$1,013,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
27,000 |
92,367 |
200,868 |
200,868 |
| Total Sell Value |
$431,015 |
$1,573,471 |
$4,354,384 |
$4,354,384 |
| Total People Sold |
2 |
3 |
3 |
3 |
| Total Sell Transactions |
2 |
4 |
6 |
6 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kennedy William James |
Director |
– • – |
2015-07-08 |
4 |
S |
$17.08 |
$290,360 |
D/D |
(17,000) |
66,490 |
|
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2015-07-01 |
4 |
S |
$16.46 |
$823,889 |
D/D |
(50,054) |
449,472 |
|
- |
|
| Hume Daniel |
Director |
– • – |
2015-06-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
| Echelard Yann |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,667 |
74,609 |
|
- |
|
| Charney Laurence N |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,667 |
83,490 |
|
- |
|
| Kennedy William James |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,667 |
83,490 |
|
- |
|
| Schoenebaum Mark |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,667 |
83,490 |
|
- |
|
| Hoberman Kenneth |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,667 |
74,446 |
|
- |
|
| Weiss Michael S |
See Remarks |
• • • |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
337,257 |
8,726,633 |
|
- |
|
| Lfb Biotechnologies S.a.s.u. |
10% Owner |
– – • |
2015-05-07 |
4 |
OE |
$0.00 |
$2,500 |
D/D |
2,500,000 |
7,614,855 |
|
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2015-04-02 |
4 |
S |
$15.51 |
$170,610 |
D/D |
(11,000) |
499,526 |
|
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2015-04-01 |
4 |
S |
$15.50 |
$198,400 |
D/D |
(12,800) |
510,526 |
|
- |
|
| Lfb Biotechnologies S.a.s.u. |
10% Owner |
– – • |
2015-02-17 |
4 |
B |
$6.53 |
$750,003 |
D/D |
114,855 |
5,114,855 |
2.45 |
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2015-01-07 |
4 |
S |
$16.40 |
$202,442 |
D/D |
(12,344) |
523,326 |
|
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2015-01-05 |
4 |
S |
$16.40 |
$886,448 |
D/D |
(54,057) |
535,670 |
|
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2014-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
589,727 |
|
- |
|
| Weiss Michael S |
See Remarks |
• • • |
2014-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
268,603 |
8,389,376 |
|
- |
|
| Weiss Michael S |
See Remarks |
• • • |
2014-12-16 |
4 |
S |
$16.44 |
$3,462,560 |
D/D |
(210,618) |
8,120,773 |
|
- |
|
| Power Sean A |
CFO, Secretary and Treasurer |
• – – |
2014-12-16 |
4 |
S |
$16.44 |
$625,394 |
D/D |
(38,041) |
579,727 |
|
- |
|
| Hoberman Kenneth |
Director |
– • – |
2014-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,223 |
|
- |
|
| Schoenebaum Mark |
Director |
– • – |
2014-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,538 |
78,823 |
|
- |
|
| Herskowitz Neil |
Director |
– • – |
2014-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,538 |
80,088 |
|
- |
|
| Kennedy William James |
Director |
– • – |
2014-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,538 |
78,823 |
|
- |
|
| Echelard Yann |
Director |
– • – |
2014-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,538 |
69,942 |
|
- |
|
| Charney Laurence N |
Director |
– • – |
2014-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
11,538 |
78,823 |
|
- |
|
125 Records found
|
|
Page 5 of 5 |
|
|
0.44 (3.16%) 
